Dr. Ben Porter-Brown

Dr. Ben Porter-Brown is an experienced drug developer with over 20 years of experience, primarily in autoimmune and inflammatory diseases, including in the OX40-OX40L space. He joined Imagene after most recently serving as the Chief Medical Officer of MoonLake Immunotherapeutics (NASDAQ: MLTX).

Prior to MoonLake Ben spent over five years at Kymab, Ltd, now a Sanofi Company, where as Vice President of Clinical Development he led the project team responsible for the development of amlitelimab, an anti-OX40 ligand monoclonal antibody, from first in human studies to the critical Phase 2a study in atopic dermatitis that resulted in the acquisition of Kymab by Sanofi. After the acquisition he took on the role of Global Project Head at Sanofi to lead the cross-functional team and further develop amlitelimab, including early commercial planning and clinical trial design in atopic dermatitis, as well as next indication selection and development plans in a variety of immune mediated diseases.

Prior to Kymab, Ben spent 16 years at Roche Pharmaceuticals in a variety of roles of increasing responsibility including Global Development Leader for Actema (tocilizumab) and Global Head of Infectious Diseases for Late-Stage Development. He received his medical degree from the Imperial College School of Science, Technology and Medicine at Imperial College London. He also holds a Bachelor of Science in Pharmacology with Medical Sciences from the University of London and a Diploma in Pharmaceutical Medicine from Vrije Universiteit Brussels.